



(12) Translation of
European patent specification

(11) NO/EP 2865663 B1

NORWAY

(19) NO
(51) Int Cl.
C07C 307/08 (2006.01)
A61K 31/18 (2006.01)
A61K 31/277 (2006.01)
A61P 25/08 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.08.07
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.04.05
(86)	European Application Nr.	13807707.8
(86)	European Filing Date	2013.06.17
(87)	The European Application's Publication Date	2015.04.29
(30)	Priority	2012.06.21, US, 201261662626 P 2012.10.04, US, 201261709737 P 2013.01.11, US, 201361751331 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	Eisai R&D Management Co., Ltd., 6-10, Koishikawa 4-chome, Bunkyo-ku, Tokyo 112-8088, JP-Japan
(72)	Inventor	KAZUTA Yuji, c/o EISAI CO. LTD. Tsukuba Research Laboratories1-3 Tokodai 5-chome, Tsukuba-shilbaraki 300-2635, JP-Japan WATANABE Toru, c/o EISAI CO. LTD. Tsukuba Research Laboratories1-3 Tokodai 5-chome, Tsukuba-shilbaraki 300-2635, JP-Japan SORIMACHI Keiichi, c/o EISAI CO. LTD. Tsukuba Research Laboratories1-3 Tokodai 5-chome, Tsukuba-shilbaraki 300-2635, JP-Japan SAITO Minako, c/o EISAI CO. LTD. Tsukuba Research Laboratories1-3 Tokodai 5-chome, Tsukuba-shilbaraki 300-2635, JP-Japan KITA Yoichi, c/o Tsukuba Research LaboratoriesEisai Co. Ltd.1-3 Tokodai 5-chome, Tsukuba-shilbaraki 300-2635, JP-Japan TANAKA Toshiaki, c/o Eisai CO. LTD.6-10 Koishikawa 4-chomeBunkyo-ku, Tokyo 112-8088, JP-Japan HIGASHIYAMA Hiroyuki, c/o EISAI CO. LTD. Tsukuba Research Laboratories1-3 Tokodai 5-chome, Tsukuba-shilbaraki 300-2635, JP-Japan HANADA Takahisa, c/o EISAI CO. LTD. Tsukuba Research Laboratories1-3 Tokodai 5-chome, Tsukuba-shilbaraki 300-2635, JP-Japan TERAMOTO Tetsuyuki, c/o EISAI CO. LTD. Tsukuba Research Laboratories1-3 Tokodai 5-chome, Tsukuba-shilbaraki 300-2635, JP-Japan KOSASA Takashi, c/o EISAI CO. LTD. Tsukuba Research Laboratories1-3 Tokodai 5-chome, Tsukuba-shilbaraki 300-2635, JP-Japan ISHIKAWA Yukio, c/o EISAI CO. LTD. Tsukuba Research Laboratories1-3 Tokodai 5-chome, Tsukuba-shilbaraki 300-2635, JP-Japan
(74)	Agent or Attorney	Tandberg Innovation AS, Postboks 1570 Vika, 0118 OSLO, Norge

(56) References

Cited:

WO-A1-2010/115952

JP-A- 2006 508 016

JP-A- 2011 523 656

US-A- 3 383 414

DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; QUAN, ZHESHAN ET AL: "Preparation of 4,5-dihydro-1,2,4-triazolo[4,3-a]quinolin- 1-one derivatives as antiepileptic agents", XP002752667, retrieved from STN Database accession no. 2006:743350 - & CN 1 807 419 A (PEOP. REP. CHINA) 26 July 2006 (2006-07-26)

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. En forbindelse eller farmasøytisk akseptabelt salt derav, som er valgt fra gruppen:

5

10

15

20

25

30

35

- 1) *N*-[(1*S*)-2,2,5,7-tetrafluor-2,3-dihydro-1*H*-inden-1-yl]sulfamid,
- 2) *N*-[(1*S*)-2,2,4,7-tetrafluor-2,3-dihydro-1*H*-inden-1-yl]sulfamid,
- 3) (+)-*N*-(2,2,4,6,7-pentafluor-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 4) *N*-[(1*S*^{*})-5-cyano-2,2-difluor-7-metyl-2,3-dihydro-1*H*-inden-1-yl]sulfamid,
- 5) (-)-*N*-(7-klor-2,2,5-trifluor-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 6) (-)-*N*-(7-klor-2,2,4-trifluor-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 7) (-)-*N*-(7-klor-2,2-difluor-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 8) (-)-*N*-(7-klor-2,2,6-trifluor-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 9) (+)-*N*-(5-klor-2,2,7-trifluor-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 10) *N*-[(1*S*)-2,2-difluor-7-metyl-2,3-dihydro-1*H*-inden-1-yl]sulfamid,
- 11) *N*-[(1*S*)-2,2,5-trifluor-7-metyl-2,3-dihydro-1*H*-inden-1-yl]sulfamid,
- 12) *N*-[(1*S*^{*})-2,2,4-trifluor-7-metyl-2,3-dihydro-1*H*-inden-1-yl]sulfamid,
- 13) *N*-[(1*S*^{*})-7-(difluormetyl)-2,2-difluor-2,3-dihydro-1*H*-inden-1-yl]sulfamid,
- 14) *N*-[(1*R*^{*},2*R*^{*})-2,4,7-trifluor-2,3-dihydro-1*H*-inden-1-yl]sulfamid,
- 15) (-)-*N*-[(1*R*^{*},2*R*^{*})-7-klor-2,4-difluor-2,3-dihydro-1*H*-inden-1-yl]sulfamid,
- 16) (+)-*N*-[(1*R*^{*},2*R*^{*})-7-klor-2,4-difluor-2,3-dihydro-1*H*-inden-1-yl]sulfamid,
- 17) (-)-*N*-[(1*R*^{*},2*R*^{*})-7-klor-2,5-difluor-2,3-dihydro-1*H*-inden-1-yl]sulfamid,
- 18) (+)-*N*-[(1*R*^{*},2*R*^{*})-4-klor-7-fluor-2-metoxi-2,3-dihydro-1*H*-inden-1-yl]-sulfamid,
- 19) (+)-*N*-(7-klor-4-fluor-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 20) (±)-*N*-(5-fluor-7-metyl-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 21) (-)-*N*-(4-fluor-7-metyl-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 22) (+)-*N*-(4-fluor-7-metyl-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 23) (+)-*N*-(7-metyl-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 24) (±)-*N*-(5-klor-7-metyl-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 25) (-)-*N*-(4-klor-7-fluor-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 26) (+)-*N*-(7-klor-5-cyano-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 27) (-)-*N*-(7-klor-5-cyano-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 28) (-)-*N*-(5-klor-7-fluor-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 29) *N*-[(1*S*)-4,7-difluor-2,3-dihydro-1*H*-inden-1-yl]sulfamid,
- 30) (+)-*N*-(7-klor-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 31) (+)-*N*-(5-cyano-7-metyl-2,3-dihydro-1*H*-inden-1-yl)sulfamid,
- 32) (-)-*N*-(5-cyano-7-metyl-2,3-dihydro-1*H*-inden-1-yl)sulfamid,

33) *N*-[(1*S*)-7-klor-5-fluor-2,3-dihydro-1*H*-inden-1-yl]sulfamid

og

34) (-)-*N*-(4,6,7-trifluor-2,3-dihydro-1*H*-inden-1-yl)sulfamid.

5 **2.** Forbindelse eller et farmasøytisk akseptabelt salt derav ifølge krav 1, som er valgt fra gruppen:

1) *N*-[(1*S*)-2,2,5,7-tetrafluor-2,3-dihydro-1*H*-inden-1-yl]sulfamid,

2) *N*-[(1*S*)-2,2,4,7-tetrafluor-2,3-dihydro-1*H*-inden-1-yl]sulfamid,

10 3) (-)-*N*-(7-klor-2,2,5-trifluor-2,3-dihydro-1*H*-inden-1-yl)sulfamid,

4) (-)-*N*-(7-klor-2,2-difluor-2,3-dihydro-1*H*-inden-1-yl)sulfamid,

5) *N*-[(1*S*)-2,2-difluor-7-metyl-2,3-dihydro-1*H*-inden-1-yl]sulfamid,

6) *N*-[(1*S*)-2,2,5-trifluor-7-metyl-2,3-dihydro-1*H*-inden-1-yl]sulfamid,

7) *N*-[(1*S*)-4,7-difluor-2,3-dihydro-1*H*-inden-1-yl]sulfamid,

15 8) *N*-[(1*S*)-7-klor-5-fluor-2,3-dihydro-1*H*-inden-1-yl]sulfamid

og

9) (-)-*N*-(4,6,7-trifluor-2,3-dihydro-1*H*-inden-1-yl)sulfamid.

3. Forbindelse ifølge krav 1, som er *N*-[(1*S*)-2,2,5-trifluor-7-metyl-2,3-dihydro-1*H*-inden-1-yl]sulfamid eller et farmasøytisk akseptabelt salt derav.

4. Forbindelse ifølge krav 1, som er (-)-*N*-(7-klor-2,2,5-trifluor-2,3-dihydro-1*H*-inden-1-yl)sulfamid eller et farmasøytisk akseptabelt salt derav.

25 **5.** Forbindelse ifølge krav 1, som er *N*-[(1*S*)-2,2,5,7-tetrafluor-2,3-dihydro-1*H*-inden-1-yl]sulfamid eller et farmasøytisk akseptabelt salt derav.

6. Forbindelse ifølge krav 1, som er *N*-[(1*S*)-2,2-difluor-7-metyl-2,3-dihydro-1*H*-inden-1-yl]sulfamid eller et farmasøytisk akseptabelt salt derav.

30

7. Forbindelse ifølge krav 1, som er *N*-[(1*S*)-4,7-difluor-2,3-dihydro-1*H*-inden-1-yl]sulfamid eller et farmasøytisk akseptabelt salt derav.

8. Et farmasøytisk preparat for behandling av epilepsi, omfattende forbindelsen eller et farmasøytisk akseptabelt salt derav ifølge hvilket som helst av kravene 1 til 7.

35

9. Forbindelse ifølge hvilket som helst av kravene 1-7, eller det farmasøytiske preparat for anvendelse ved en metode for behandling av epilepsi.